In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwin Elmhirst

Data Journalist

Edwin is a healthcare journalist with a passion for data and analysis. He graduated with a master's degree in biomedical sciences and spent some time in postgraduate research before moving into journalism. Edwin's skills in data science and scientific analysis allow him to identify trends, develop insights, and tell compelling stories using data.

Latest From Edwin Elmhirst

Investment In New Products: Looking Beyond The R&D Line

Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.

Outlook 2024 Research & Development

Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?

Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound.

Commercial Companies

Tempest Changes The Atmosphere

An analysis of shareholders’ reactions to clinical data shows a generally dismal environment punctuated by a few huge positive moves.

Clinical Trials Commercial

It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever

But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.

Deals Cancer

As Time Ticks, Industry Edges Closer To The Big Patent Cliff

Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.

Business Strategies Commercial

A Closer Look: Commercial Impact For Drugs Up For Medicare Price Negotiation

An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.

Market Access Medicare
See All